The Aramon plant (30) in Seqens is one of the fourteen French sites of this global player integrated in pharmaceutical synthesis and personalized ingredients (for the health, electronics, cosmetics and food industries).
Within the framework of the Industry Recovery Plan, three structuring projects of this French mid-sized company have been selected by the French government. Including that of a new unit for the production of highly active ingredients (HPAPI), in Aramon.
“This new unit will complement the one inaugurated last August in Villeneuve-la-Garenne (Hauts-de-Seine, NDLR), says Julien Pignol, director of the Aramon site. It will enable Seqens to be positioned as a key player in the field of highly active ingredients, both in terms of production capacity but also of know-how and skills. “
The very buoyant HPAPI market
With global demand growing in the order of 8% to 10% each year, HPAPIs now represent 25% …